Javascript must be enabled to continue!
Antiproliferative Effects of Interferon-αCon1 on Ovarian Clear Cell Adenocarcinoma In vitro and In vivo
View through CrossRef
Abstract
Purpose: We examined the antiproliferative effect of IFN-αCon1 and its mechanism on ovarian clear cell adenocarcinoma in vitro and in vivo.
Experimental Design: (a) The effects of IFN-αCon1 on growth, morphology, cell cycle, and type I IFN-α receptor (IFNAR-2) expression were examined on two ovarian clear cell adenocarcinoma cell lines (KOC-5C and KOC-7C) in vitro. (b) KOC-5C or KOC-7C cells were transplanted into nude mice, and changes in tumor volume, tumor weight, apoptosis, necrosis, and microvessel density were investigated. The expression of angiogenesis factors was examined in the serum and the developed tumors.
Results: Both cell lines expressed IFNAR-2 mRNA, but its protein was detected only in KOC-7C. In KOC-7C cells, antiproliferative effects were observed in a time- and dose-dependent manner and cell division was blocked at the S phase. The KOC-7C tumors showed decreases in tumor volume and weight; a decreasing tendency in basic fibroblast growth factor (bFGF), vascular endothelial growth factor, and interleukin (IL)-8 protein expression in the tumor; a significant decrease in bFGF and IL-8 protein expression in the serum, and of microvessel density; and significant increase in apoptosis and necrosis in the tumor. In the KOC-5C tumors, these in vitro and in vivo changes were not apparent, and the antiproliferative effects of IFN-αCon1 were not obvious.
Conclusions: IFN-αCon1 suppresses tumor proliferation by inducing apoptosis, blocking the cell cycle, and inhibiting tumor angiogenesis. Our findings show that the clinical efficacy of IFN-αCon1 can be predicted by examining IFNAR-2 expression on tumor cells, and the efficacy of IFN-αCon1 treatment can be evaluated by measuring serum bFGF and IL-8 levels.
American Association for Cancer Research (AACR)
Title: Antiproliferative Effects of Interferon-αCon1 on Ovarian Clear Cell Adenocarcinoma
In vitro
and
In vivo
Description:
Abstract
Purpose: We examined the antiproliferative effect of IFN-αCon1 and its mechanism on ovarian clear cell adenocarcinoma in vitro and in vivo.
Experimental Design: (a) The effects of IFN-αCon1 on growth, morphology, cell cycle, and type I IFN-α receptor (IFNAR-2) expression were examined on two ovarian clear cell adenocarcinoma cell lines (KOC-5C and KOC-7C) in vitro.
(b) KOC-5C or KOC-7C cells were transplanted into nude mice, and changes in tumor volume, tumor weight, apoptosis, necrosis, and microvessel density were investigated.
The expression of angiogenesis factors was examined in the serum and the developed tumors.
Results: Both cell lines expressed IFNAR-2 mRNA, but its protein was detected only in KOC-7C.
In KOC-7C cells, antiproliferative effects were observed in a time- and dose-dependent manner and cell division was blocked at the S phase.
The KOC-7C tumors showed decreases in tumor volume and weight; a decreasing tendency in basic fibroblast growth factor (bFGF), vascular endothelial growth factor, and interleukin (IL)-8 protein expression in the tumor; a significant decrease in bFGF and IL-8 protein expression in the serum, and of microvessel density; and significant increase in apoptosis and necrosis in the tumor.
In the KOC-5C tumors, these in vitro and in vivo changes were not apparent, and the antiproliferative effects of IFN-αCon1 were not obvious.
Conclusions: IFN-αCon1 suppresses tumor proliferation by inducing apoptosis, blocking the cell cycle, and inhibiting tumor angiogenesis.
Our findings show that the clinical efficacy of IFN-αCon1 can be predicted by examining IFNAR-2 expression on tumor cells, and the efficacy of IFN-αCon1 treatment can be evaluated by measuring serum bFGF and IL-8 levels.
Related Results
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
The Impact of IL28B Gene Polymorphisms on Drug Responses
The Impact of IL28B Gene Polymorphisms on Drug Responses
To achieve high therapeutic efficacy in the patient, information on pharmacokinetics, pharmacodynamics, and pharmacogenetics is required. With the development of science and techno...
P-677 fasting-mimicking diet delays ovarian aging by modulating immune cells and enhancing glycocholic acid levels
P-677 fasting-mimicking diet delays ovarian aging by modulating immune cells and enhancing glycocholic acid levels
Abstract
Study question
Does fasting-mimicking diet (FMD) alleviate ovarian aging in mice, and what roles do gut and serum metab...
P–688 Assessment of ovarian vascularity by three-dimensional vaginal power Doppler on day two of menstrual cycle to predict the number of mature eggs collected
P–688 Assessment of ovarian vascularity by three-dimensional vaginal power Doppler on day two of menstrual cycle to predict the number of mature eggs collected
Abstract
Study question
Could ovarian vascularity indices, measured by 3-dimensional (3D) vaginal power Doppler, predict the num...
Ovarian seromucinous carcinoma: an independent epithelial ovarian cancer?
Ovarian seromucinous carcinoma: an independent epithelial ovarian cancer?
Abstract
Background
2020 World Health Organization Classification of Female Genital Tumors removed ovarian seromucinous carcinoma as a distinct enti...
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Objective: To determine the frequency of common chromosomal aberrations in local population idiopathic determine the frequency of common chromosomal aberrations in local population...
Abstract MIP-048: SHORT-FORM RON KINASE AS A NOVEL THERAPEUTIC TARGET IN OVARIAN CANCER
Abstract MIP-048: SHORT-FORM RON KINASE AS A NOVEL THERAPEUTIC TARGET IN OVARIAN CANCER
Abstract
BACKGROUND: Although 70–80% of women respond to standard platinum-based chemotherapy, a majority of patients will develop recurrent platinum-resistant disea...
Plasmacytoid Dendritic Cells Mediate Myocardial Ischemia/Reperfusion Injury by Secreting Type I Interferons
Plasmacytoid Dendritic Cells Mediate Myocardial Ischemia/Reperfusion Injury by Secreting Type I Interferons
Background
We previously demonstrated that ischemically injured cardiomyocytes release cell‐free DNA and HMGB1 (high mobility group box 1 protein) into circulation duri...

